@RaceOncology - Given RC220 is not ready to be used in the clinic can the Sheba AML trial use RC220 to conclude their AML trial so we can final report although there may not be any significant impact from it? If not, what are the dependencies?
When can we expect research publications in high impact journals? Feels like we have been waiting for some time on this front.
Hopefully we will get some info on the above soon in our quarterly.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.20 |
Change
-0.040(3.23%) |
Mkt cap ! $208.4M | |||
| Open | High | Low | Value | Volume |
| $1.24 | $1.24 | $1.20 | $103.7K | 85.92K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 12091 | $1.20 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.22 | 9720 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
| RAC (ASX) Chart |